Navigation Links
A More Convenient HIV Treatment Is as Effective as More Complex Regimens

h the approval of new dosage formulations, this information could improve the management of patients in this country and in regions of the world where access to medical care and treatment compliance can be challenging," said AHRQ Director Carolyn M. Clancy, M.D. “These findings highlight the need for additional research that evaluates the extent to which improvements in markers of a disease, such a viral suppression, lead to improved clinical outcomes.”

The Centers for Disease Control and Prevention estimates that between 1 million and 1.2 million people in the United States are living with HIV, and at least 40,000 new infections occur each year. Worldwide, approximately 40 million individuals are infected with the virus.

Researchers, led by Roger Chou, M.D., at Oregon Health & Science University in Portland, completed an analysis of 26 trials, including 12 head-to-head trials comparing NNRTI-based regimens with protease inhibitor-based regimens. Fourteen other trials compared two-drug regimens with either NNRTI-based or protease inhibitor-based, triple-drug regimens. Among 3,337 patients analyzed in the head-to-head trials, NNRTI-based regimens were better than protease inhibitor-based regimens by 20 percent to 60 percent in their ability to achieve viral suppression.

Dramatic decreases in the rate of HIV-related illnesses and deaths have occurred since the introduction of HAART therapy in which three or more antiretroviral agents are used. However, until now, comparisons of head-to-head trials were not available to support selection of a protease inhibitor or an NNRTI as part of that combination therapy. Researchers concluded that earlier analyses may be unreliable because their results differed dramatically from the analysis of head-to-head trials, even after excluding patients who had previously received HIV therapy and those who had received older NNRTIs, such as delaviridine, that are now used infrequently because they are l
'"/>




Page: 1 2 3

Related medicine news :

1. Inhalants: The New, Convenient High for Kids and Teens
2. Advances in Treatment of Cataracts
3. Recommendations for Treatment of Blood Pressue
4. Treatment for Menieres disease
5. Treatment for pre-menstrual syndrome is ineffective
6. Better Treatment for obesity
7. Gene Treatment for Heart Disease
8. More People Seeking Treatment for Depression
9. Focused Treatment For Childhood Cancer
10. Inadequate Drug Treatment For Youth
11. FDA Approves New surgery Treatment for Farsightedness
Post Your Comments:
(Date:8/29/2008)...ug. 29 /PRNewswire-FirstCall/ -- Landauer, Inc. (N...ors declared a regular,quarterly cash dividend of ...008. The dividend will be paid on October 3, 2008,... About Landauer, Landauer is the leading provide... and environmental radiation exposure. For more th...
(Date:8/29/2008)...fic obligation reduced from $250 to $19 million, ...oston Scientific,Corporation (NYSE: BSX ) today a... Texas found two patents of Medtronic, Inc. (NYSE:...ng the prosecution of the patents,before the Unite... previously found that certain Boston Scientific b...
(Date:8/29/2008)... Dr. Milton Owens and the Coastal Center for O...ia to provide protection for cash paying patients ...ic community is benefiting. , .... Milton Owens and the Coastal Center for Obesity ...rovide protection for cash paying patients in the ...
(Date:8/29/2008)... Trusted life science software provider allows...ngage via GSA. , Reston, ...erging software engineering firm dedicated to the...ral Services Administration (GSA) Contract. The GS...h the ability to conveniently engage 5AM Solutions...
Breaking Medicine News(10 mins):Health News:Court Rejects Two Medtronic Patents 2Health News:Court Rejects Two Medtronic Patents 3Health News:Coastal Center for Obesity Offers Hispanics Weight Loss Surgery with a Warranty 2Health News:Federal and State Agencies Have Easier Access to 5AM Solutions' Award-Winning Software Services 2
...development at Sandia National Laboratories can id...rax in less than five minutes. //Sandia's Laborato...rted the work. Sandia is a multiprogram laboratory...kheed Martin company, for the U.S. Department of E...
...ng great covenant in dental restorative work, say ... and Technology at Ohio.//This ACP has new physica... researcher at OSU. “It’s more soluble than other ...to the stable dental mineral hydroxyapatite, which...
... and Iceland's National University Hospital, ascer...ses a woman's risk by more than 62 per cent.//Endo... tissue, which is normally found only in the linin...he tissue attaches itself to ligaments and organs ...
...e today are more at risk of developing stomach can...earchers at the University of Newcastle believe th... have robbed it off its anti-cancer agents. The r...h indicates that Aspirin may be effective in fight...
Other Medicine News:
(Date:8/27/2008)...in Parts of Bucks, Delaware, Montgomery,Philadelp...e-USNewswire/ -- After encouraging,results followi...tment of,Environmental Protection will continue it...st the mosquito-borne West Nile virus., Targeted ....m. and,midnight in portions of Bucks, Delaware, M...
(Date:8/27/2008)..., melphalan and prednisone arm demonstrated a, si... complete response -, CAMBRIDGE, Mass., Aug. 27 /...pany today announced the publication of results fr... trial in this week,s edition of the,New England J...nt survival,benefit and a 30 percent complete remi...
(Date:8/27/2008)...7 /-, - Oralair(R) Grasses...acodynamic Study Conducted in an Allergen Challeng... positive results of a new study,conducted in an A...alair(R) Grasses included 86 adult patients expose...nt durations: 1 week, 1 month,2 and 4 months with...
(Date:8/27/2008)...rom BLISS-52 trial, expected by mid-2009 - - Data...fall 2009 -, ROCKVILLE, Md., Aug. 27 /PRNewswire-... HGSI ) today announced it has completed enrollme...wo pivotal Phase 3,randomized clinical trials of L... systemic lupus erythematosus (SLE). Belimumab is ...
Breaking Medicine Technology:DEP to Complete Aerial Mosquito Treatments to Stem West Nile Virus in Southeastern Counties 2DEP to Complete Aerial Mosquito Treatments to Stem West Nile Virus in Southeastern Counties 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 2New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 4New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 5New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 6Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber 2Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 2Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 4Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 5Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 6Hiemstra Approved to Manufacture Medical Devices in New CER 9345 1Hiemstra Approved to Manufacture Medical Devices in New CER 9345 2TeamStaff Receives Nasdaq Determination Letter 9340 1TeamStaff Receives Nasdaq Determination Letter 9340 2TeamStaff Receives Nasdaq Determination Letter 9340 3Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Cli 1178 1Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Cli 1178 2Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Cli 1178 3Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Cli 1178 4Chromosome Abnormalities Raise Risk for Autism 9333 1Chromosome Abnormalities Raise Risk for Autism 9333 2Chromosome Abnormalities Raise Risk for Autism 9333 3Chromosome Abnormalities Raise Risk for Autism 9333 4
...Family History of ESRD Are at High,Risk , ,WASHIN...f U.S.,adults have a family history of end-stage r...to be at increased risk of developing,kidney disea...l of,the American Society of Nephrology. , "A fami...frican-Americans, who are also at substantially hi...
...ibody significantly reduced the number of,new or e...bmitted,for presentation at upcoming medical meeti...12, 2007,/PRNewswire-FirstCall/ -- Biogen Idec, In...hat the ongoing CHOICE trial, a Phase 2,randomize...zumab,met its primary endpoint in relapsing multi...
Other Medicine Technology:Nearly 1 in 10 Americans Has A Relative With Kidney Failure 2Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients,With Relapsing Multiple Sclerosis 2Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients,With Relapsing Multiple Sclerosis 3Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients,With Relapsing Multiple Sclerosis 4Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients,With Relapsing Multiple Sclerosis 5
...nterior Spinal Implant system. Material that has a...cal bone. The result is an implant that meets the ..., while optimizing the fusion environment through ...omic design with 5 and 10 degrees of lordosis. Min...
...Cage System provides anterior column support for s...ctomies from T1 to L5. The system consists of one ...tacked to a desired height, accommodating various ...lymer material emulates the biomechanical properti...
The primary goals in interbody fusion are to immobilize the affected vertebrae, to restore disc space height and sagittal alignment, and to provide an enviroment for bone fusion between vertebral bod
Flexoscope images are transmitted through sorted fiberglass bundles that record the picture and transmit it to a user's eye. Karl Storz flexoscopes are designed for rough, industrial handling and can
Medicine Products: